CDK4/6 inhibitor ribociclib and doxorubicin combination treatment inhibits breast cancer bone metastasis and enhances T-cell targeted therapy
Authors:
- Xinming SuXSXinming Su
- Takayuki KobayashiTKTakayuki Kobayashi
- Jingyu XiangJXJingyu Xiang
- Yalin XuYXYalin Xu
- Ayesha N. Shajahan-HaqASAyesha N. Shajahan-Haq
- Mahta MardaniMMMahta Mardani
- Suleyman NoordeenSNSuleyman Noordeen
- Kaylee O’DOnnellKOKaylee O’DOnnell
- Kristin A. KwakwaKKKristin A. Kwakwa
- Dennis GuanDGDennis Guan
- Gregory C. FoxGFGregory C. Fox
- Francesca FontanaFFFrancesca Fontana
Open Access
- 25 April 2026
- journal article
- Published by Elsevier in Journal of Bone Oncology
- Vol. 58
Abstract
No abstract availableKeywords
Funding Information
- Hope Center for Neurological Disorders, Washington University in St. Louis
- U.S. Department of War (W81XWH-16-1-0286)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30-AR074992)
- Cancer Prevention and Research Institute of Texas (F30CA254215)
- Cancer Prevention and Research Institute of Texas (RR220013)
- Cancer Prevention and Research Institute of Texas (R01CA248526)
- Cancer Prevention and Research Institute of Texas (R01CA237263)
- Musculoskeletal Research Center, Washington University in St. Louis
- Washington University in St. Louis (NCI S10 OD02742)
- Novartis
- National Institutes of Health (U54CA199092)
- National Cancer Institute (P01 CA100730)
- National Cancer Institute (R01 CA216840)
- School of Medicine, Washington University in St. Louis (T32CA009547)
This publication has 44 references indexed in Scilit:
- The landscape of cyclin-dependent kinase 4/6 inhibitors in solid malignancies: emphasis on immunotherapy combinatorial strategiesMedical Oncology, 2025
- Multimodal data integration in early-stage breast cancerThe Breast, 2025
- Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, −3, and −7 trialsEuropean Journal of Cancer, 2025
- Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: Relief from immunosuppression is associated with clinical responseEBioMedicine, 2022
- Targeting cell-cycle machinery in cancerCancer Cell, 2021
- Mechanisms of Sensitivity and Resistance to CDK4/6 InhibitionCancer Cell, 2020
- Chemotherapy and CDK4/6 Inhibition in Cancer Treatment: Timing Is EverythingCancer Cell, 2020
- Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cellsMolecular Oncology, 2017
- Alterations of thep53, Rb andMDM2 genes in osteosarcomsJournal of Cancer Research and Clinical Oncology, 1996
- The retinoblastoma protein and cell cycle controlCell, 1995